Abbott Laboratories (NYSE:ABT) Shares Acquired by Schrum Private Wealth Management LLC

Schrum Private Wealth Management LLC increased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 41.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,610 shares of the healthcare product maker's stock after purchasing an additional 4,895 shares during the quarter. Abbott Laboratories makes up approximately 1.0% of Schrum Private Wealth Management LLC's investment portfolio, making the stock its 25th biggest position. Schrum Private Wealth Management LLC's holdings in Abbott Laboratories were worth $1,894,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Insight Folios Inc increased its stake in Abbott Laboratories by 3.3% in the 3rd quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock worth $307,000 after buying an additional 87 shares in the last quarter. Boltwood Capital Management increased its stake in Abbott Laboratories by 0.4% in the 3rd quarter. Boltwood Capital Management now owns 21,821 shares of the healthcare product maker's stock worth $2,488,000 after buying an additional 89 shares in the last quarter. Wedge Capital Management L L P NC increased its stake in Abbott Laboratories by 2.9% in the 3rd quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock worth $359,000 after buying an additional 89 shares in the last quarter. Silicon Valley Capital Partners increased its stake in Abbott Laboratories by 8.7% in the 3rd quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock worth $126,000 after buying an additional 89 shares in the last quarter. Finally, Atwood & Palmer Inc. grew its position in shares of Abbott Laboratories by 6.5% during the third quarter. Atwood & Palmer Inc. now owns 1,478 shares of the healthcare product maker's stock valued at $169,000 after purchasing an additional 90 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ABT has been the subject of a number of research analyst reports. UBS Group raised their price objective on Abbott Laboratories from $143.00 to $146.00 and gave the company a "buy" rating in a research report on Thursday, October 17th. Raymond James restated a "buy" rating and set a $129.00 price objective (up previously from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Oppenheimer started coverage on Abbott Laboratories in a research report on Tuesday, October 8th. They issued an "outperform" rating and a $130.00 price target for the company. Evercore ISI lifted their price target on Abbott Laboratories from $120.00 to $124.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Finally, Jefferies Financial Group lifted their price target on Abbott Laboratories from $120.00 to $125.00 and gave the stock a "hold" rating in a research report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $130.07.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of Abbott Laboratories stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the transaction, the chief executive officer now directly owns 220,059 shares of the company's stock, valued at approximately $25,617,068.19. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.10% of the stock is currently owned by corporate insiders.

Abbott Laboratories Trading Down 0.6 %

Shares of Abbott Laboratories stock traded down $0.70 on Wednesday, hitting $115.74. 4,719,871 shares of the company traded hands, compared to its average volume of 5,704,782. The stock's 50 day moving average price is $115.43 and its 200-day moving average price is $109.35. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 52 week low of $96.20 and a 52 week high of $121.64. The company has a market cap of $200.75 billion, a PE ratio of 35.25, a PEG ratio of 2.74 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.01. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. Abbott Laboratories's revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $1.14 earnings per share. Equities research analysts predict that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 1.90%. The ex-dividend date of this dividend is Tuesday, October 15th. Abbott Laboratories's payout ratio is 66.87%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.